Castle Biosciences Approved For Dual Listing On Nasdaq Texas
(RTTNews) - Castle Biosciences, Inc. (CSTL), a diagnostics company developing innovative tests to guide patient care, announced that its common stock has been approved for a dual listing on Nasdaq Texas, while maintaining its primary listing on The Nasdaq Global Market under the ticker "CSTL."
Nasdaq Texas Listing
Castle announced today that it had received approval for a dual listing on Nasdaq Texas, while retaining its primary listing on The Nasdaq Global Market.
The additional listing is expected to enhance the company's visibility among investors and reflects Castle's Texas roots and strong connection to the state's growing life sciences and innovation ecosystem.
The dual listing will not affect Castle's business operations, reporting requirements, capital structure or investors' ability to trade its common stock.
Second Quarter 2026 Results
Castle recently reported second-quarter revenue of $103.5 million, compared with $86.2 million in the prior-year quarter, supported by continued growth across its core diagnostic testing portfolio.
Total test reports from key revenue drivers, including DecisionDx-Melanoma and TissueCypher, increased 32% year over year.
DecisionDx-Melanoma test reports rose to 10,280 from 9,981, while TissueCypher Barrett's Esophagus test reports increased to 14,988 from 9,170 in Q2 2025.
Gross margin was 75%, compared with 77% in the prior-year quarter, while adjusted gross margin was 76%, down from 80% a year earlier.
Castle reported a net loss of $2.1 million, or $0.07 per share, compared with net income of $4.5 million, or $0.16 per share, in Q2 2025.
Adjusted EBITDA increased to $12.4 million, compared with $10.4 million in the prior-year quarter.
Business & Pipeline Updates
On June 25, 2026, Castle announced that DecisionDx-Melanoma's integrated sentinel lymph node biopsy result, i31-SLNB, outperformed the Melanoma Institute Australia nomogram in identifying patients at low and high risk of sentinel lymph node positivity.
On July 14, 2026, Castle announced that its AdvanceAD-Tx test received final approval from the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program, bringing all tests across the company's dermatology and ophthalmology portfolios under New York State approval.
On June 10, 2026, Castle and SciBase announced enrollment of the first patient in DETECT-AD, a multicenter prospective clinical study evaluating electrical impedance spectroscopy (EIS) for the early prediction of atopic dermatitis flares, with the aim of enabling proactive treatment and improving patient care.
2026 Outlook
Castle raised its full-year 2026 revenue guidance to $365 million-$375 million, compared with its previous guidance of $345 million-$355 million. Total revenue in 2025 was $344.2 million.
The company also expects to achieve positive Adjusted EBITDA in the third quarter, fourth quarter and full year 2026, supported by continued revenue growth and improving operating leverage.
Cash Position
As of June 30, 2026, Castle Biosciences had $266.8 million in cash, cash equivalents and marketable investment securities, providing financial support for continued investment in its diagnostic testing portfolio and pipeline initiatives.
CSTL has traded between $17.72 and $44.28 over the past year. Currently, CSTL is trading at $30.15, up 1.79%.
